Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Catherine A. Knupp"'
Publikováno v:
British Journal of Clinical Pharmacology. 54:255-261
Aims The aims of the study were to evaluate the bioavailability of didanosine from the encapsulated enteric coated beads (1 × 200 mg; enteric beads) and enteric coated mini-tablets (4 × 50 mg; enteric tablet) formulations relative to the chewable/d
Autor:
Vincent J. Carey, Catherine A. Knupp, Lisa M. Frenkel, Florence H. Yong, Robert C. Stevens, John H. Rodman
Publikováno v:
AIDS Research and Human Retroviruses. 16:415-421
The effect of food on didanosine bioavailability and interpatient pharmacokinetic variability was examined in children infected with human immunodeficiency virus type 1 (HIV-1). Didanosine pharmacokinetics were determined during fasting and fed condi
Autor:
Ralph H. Raasch, George E. Dukes, Catherine A. Knupp, Dion F. Coakley, Ronald J. Falk, Sanjeev Kaul, Rashmi H. Barbhaiya, Lawrence J. Hak, Brian E. Wagner, Charles van der Horst
Publikováno v:
Clinical Pharmacology & Therapeutics. 60:535-542
Objective To evaluate the pharmacokinetics of didanosine in patients with normal kidney function or chronic kidney failure. Methods Three groups of patients with human immunodeficiency virus (HIV) infection were studied: group I, six men with normal
Publikováno v:
European Journal of Clinical Pharmacology. 45:409-413
The pharmacokinetics of orally-administered didanosine were evaluated in 6 male and 6 female HIV seropositive patients to determine the effect of pretreatment with metoclopramide, an inducer of gastrointestinal motility, and loperamide, which retards
Publikováno v:
The Journal of Clinical Pharmacology. 33:568-573
The effect of the time of food administration on the bioavailability of didanosine, administered as a 300-mg dose of a chewable tablet formulation, was evaluated in 10 men seropositive for the human immunodeficiency virus (HIV), but free of any sympt
Autor:
Timothy P. Cooley, Rashmi H. Barbhaiya, Raphael Dolin, Mindell Seidlin, Catherine A. Knupp, Nancy Gustafson, Marcel Rozencweig, Mohan Beltangady
Publikováno v:
Clinical Infectious Diseases. 16:S26-S31
The relation between the average steady-state plasma concentration (Cpss) of didanosine and selected measures of efficacy, such as CD4 cell count, p24 antigenemia, and weight gain, was evaluated in patients participating in a phase 1 safety and pharm
Autor:
Catherine A. Knupp, James S. Lee, Rashmi H. Barbhaiya, Elizabeth A. Morgenthien, Wen Chyi Shyu
Publikováno v:
Pharmaceutical Research. 10:1157-1164
Didanosine is a purine nucleoside analogue approved for the treatment of human immunodeficiency virus infection. It is extremely unstable at pH values less than 3 and requires protection against gastric acid-induced hydrolysis. Beagle dogs pretreated
Publikováno v:
Antimicrobial Agents and Chemotherapy. 36:1382-1386
The interaction potential between cefepime and amikacin was investigated in a steady-state pharmacokinetic study in 16 healthy male subjects. Eight subjects (group A) received a first course of 2,000 mg of cefepime; this was followed by a second cour
Publikováno v:
Antimicrobial Agents and Chemotherapy. 36:1181-1185
The effects of age and gender on the pharmacokinetics of cefepime were examined in 48 volunteers following administration of a single 1,000-mg intravenous dose. Male and female subjects were divided into four groups, each consisting of 12 subjects, a
Autor:
Randall K. Nakahiro, Catherine A. Knupp, David A. Sclar, Albert E. Yellin, Mark A. Gill, Thomas V. Berne, Mark P. Okamoto, Alfred Chin, Maria D. Appleman, Peter N.R. Heseltine
Publikováno v:
Therapeutic Drug Monitoring. 14:220-225
Cefepime is a new broad-spectrum cephalosporin with activity against Staphylococcus, Streptococcus, Pseudomonas, and the Enterobacteriaceae. The purpose of this study was to measure cefepime concentrations in plasma, peritoneal fluid, bile fluid and